替非珠单抗

化合物

替非珠单抗INN:Tefibazumab)是一种人源化单克隆抗体,用于治疗金黄色葡萄球菌的严重感染。可能的适应症包括治疗患有囊性纤维化的2a期患者的金黄色葡萄球菌[1]耐甲氧西林金黄色葡萄球菌[2]该药物由Inhibitex开发的。[3]

替非珠单抗
单克隆抗体
种类完整抗体
目标聚集因子A英语Clumping factor A
临床资料
商品名英语Drug nomenclatureAurexis
其他名称特非珠单抗、INH-H 2002
ATC码
  • 未分配
识别信息
CAS号521079-87-8  ☒N
ChemSpider
UNII
KEGG
化学信息
化学式C6548H10122N1730O2034S44
摩尔质量147,035.72 g·mol−1

参见

参考资料

  1. ^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
  2. ^ Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents on Anti-Infective Drug Discovery. January 2008, 3 (1): 10–33. PMID 18221183. doi:10.2174/157489108783413173. 
  3. ^ John JF. Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection. Current Opinion in Molecular Therapeutics. October 2006, 8 (5): 455–60. PMID 17078388.